Evidence map›Paper›PMID 38367868›Full record

ReviewPharmacology & therapeutics2024

The therapeutic potential of targeting the CHD protein family in cancer.

Min Zhang, Kaiyuan Wu, Weijie Zhang, Xia Lin, Qi Cao, Lili Zhang, Kaifu Chen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Min ZhangZhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China.
Kaiyuan WuBasic and Translational Research Division, Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Department of Bioengineering, Rice University, Houston, TX 77005, USA.
Weijie ZhangZhejiang Provincial Key Laboratory of Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China; Department of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Xia LinZhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China.
Qi CaoDepartment of Urology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Lili ZhangBasic and Translational Research Division, Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Prostate Cancer Program, Dana-Farber and Harvard Cancer Center, Harvard University, Boston, MA 02115, USA.
Kaifu ChenBasic and Translational Research Division, Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Prostate Cancer Program, Dana-Farber and Harvard Cancer Center, Harvard University, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: Kaifu.Chen@childrens.harvard.edu.
Boston Children's Hospital · USZhejiang University · CNFirst Affiliated Hospital Zhejiang University · CNHarvard University · USNorthwestern University · US

Funding

Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
Transcription Factor 4 Maintain Endothelial identity to Oppose Heart FailureR01HL155632 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Lili Zhang · 2022 to 2026
$2.5M
A non-canonical role for EZH2 in rRNA methtlationR01CA256741 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CAO, QI · 2021 to 2025
$2.1M
A novel role for EZH2 in A-to-I RNA editing in prostate cancerR01CA278832 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Qi Cao, Kaifu Chen · 2024 to 2026
$2.0M
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancerR01CA208257 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CAO, QI · 2017 to 2022
$1.8M
Bioinformatics Techniques to Analyze Dynamic Changes of 3D GenomeR01GM138407 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI CHEN, KAIFU · 2022 to 2025
$1.8M
Role of S-nitrosylation in TransdifferentiationR01HL133254 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2018 to 2021
$1.6M
Computational epigenetics modeling of cell identity genesR01GM125632 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU · 2018 to 2021
$1.4M
NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA208257NCI NIH HHS R01 CA256741NCI NIH HHS R01 CA278832NHLBI NIH HHS R01 HL133254NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R01 HL155632NIGMS NIH HHS R01 GM125632NIGMS NIH HHS R01 GM138407US Department of Defense W81XWH-17-1-0357US Department of Defense W81XWH-19-1-0563US Department of Defense W81XWH-20-1-0504
6 · The paper itself

Abstract

Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-of-function mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment.

Indexed as

ChromatinNeoplasmsChromatin Assembly and DisassemblyDNA-Binding ProteinsDNA HelicasesEpigenesis, GeneticHumansMutationChromatinDNA-Binding ProteinsDNA HelicasesCancer developmentChromatin remodelingEpigenetic regulationTherapeutic strategies

Identifiers

PMID38367868
PMCPMC10942663
OpenAlexW4391849985

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.